Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Withdraws $126M Stock Offering

NEW YORK, Oct. 16 - Orchid Biosciences has withdrawn a proposed follow-on public offering of over 21/2 million shares of new stock, the Princeton, N.J. company announced Monday.

The manufacturer of SNP scoring technology filed the follow-on public offering with the Securities and Exchange Commission September 22. The total offering was valued at $126,143,500, according to the filing, and included a total of 4,025,000 shares of common stock: the 2 1/2 million new shares, one million existing shares, and additional " green shoe" shares.

Orchid’s withdrawal of its follow-on public offering does not appear to be related to its anticipated third quarter earnings.

“The decision is solely due to market conditions,” said Barbara Lindheim, Orchid’s vice president of strategic communications. “At the time we filed with the SEC, our sector was stronger and our stock was stronger.”

Since September 1, Orchid's stock has plunged from 43 7/16 down to 19 7/16, where it was trading Monday at midday. The NASDAQ, on which the company’s shares are traded, was down 18.5 percent for the year at the close of trading Friday.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.